Andrew focuses his practice on public and private securities offerings, liability management transactions and corporate governance matters. He has experience representing issuers and underwriters in a range of securities offerings and transactions, including Rule 144A and registered offerings of debt securities, initial public offerings, follow-on offerings of common and preferred stock, exchange offers, tender offers, consent solicitations and redemptions.
He also advises public companies regarding 1934 Act reporting and annual meeting proxy statement matters. Additionally, Andrew has represented public and private companies in mergers and acquisitions and other corporate transactions.
Prior to joining McGuireWoods, Andrew worked for over six years in the New York City office of a top-ranked global law firm on a wide range of capital markets transactions. During that time he was also seconded into the legal department of the capital markets group of a multinational financial institution.
Before law school, Andrew earned his doctorate in Philosophy and taught Philosophy at Austin College in Sherman, Texas; Washington and Lee University in Lexington, Virginia; and Rhodes College in Memphis, Tennessee.
Experience
- Representation of Titan Partners Group, a division of American Capital Partners, as sole bookrunner, in connection with a $15.0 million public offering of common stock and pre-funded warrants by enVVeno Medical Corporation (Nasdaq: NVNO), a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease.
- Representation of Titan Partners Group, a division of American Capital Partners, as sole bookrunner, in connection with the $22.4 million initial public offering of common stock by Actuate Therapeutics, Inc. (Nasdaq: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers.
- Representation of Newbridge Securities Corporation, as exclusive placement agent, in connection with a $3.4 million registered direct offering of ordinary shares and pre-funded warrants by Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq:IINN), an innovative medical technology company in the life support arena.
- Representation of Titan Partners Group, a division of American Capital Partners, as sole bookrunner, in connection with an $11.0 million public offering of common stock and pre-funded warrants by Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company leading the discovery and development of next generation allosteric therapies.
- Representation of Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, in its private placement with several healthcare-focused institutional investors priced at market per Nasdaq rules consisting of a) an initial tranche of aggregate $8.0 million in gross proceeds for shares of the company’s Series B-1 Convertible Preferred Stock and warrants to purchase shares of the Company’s Series B-3 Convertible Preferred Stock and (b) a subsequent tranche of aggregate $8.0 million in gross proceeds from the exercise of the warrants upon the achievement of certain operational and commercial milestones.
- Representation of Alliance Global Partners, as exclusive placement agent, in connection with a $3 million follow-on equity offering by Versus Systems Inc. (Nasdaq: VS), an engagement and rewards company that makes live events, games, shows, and apps more fun to watch and play.
- Representation of a major financial institution in connection with public offerings of senior notes.
- Representation of a major financial institution in connection with public offerings of preferred stock.
- Representation of a major consumer products company in connection with a Rule 144A offering of $800 million of senior notes.
- Representation of an international biopharmaceutical company in a public offering of American Depositary Shares.
- Representation of a multi-office medical practice in a corporate reorganization and a $25 million minority preferred equity investment.
-
University of Virginia School of LawJD
Articles Development Editor, Virginia Law Review
- Duke UniversityPhDPhilosophy
-
State University of New York at GeneseoBAPhilosophy
summa cum laude
Member, New York City Bar Association
Member, American Bar Association
Member, North Carolina Bar Association
Member, Mecklenburg County Bar Association
- Author, SEC Permits Use of Electronic Signatures in EDGAR Filings, McGuireWoods Legal Alert, December 28, 2020
- North Carolina
- New York
The rules of professional conduct in some jurisdictions require disclosure of selection methodology for certain public accolades and recognitions. Click here to view available selection methodologies.
Selected for inclusion in Best Lawyers: Ones to Watch, Securities/Capital Markets Law, 2023, 2024, 2025